MANUFACTURER CHOICE OF DEVICE TO UNDERGO DESIGN CONTROL INSPECTION "REASONABLE APPROACH," FDAer SAYS; HIMA SETS UP WEB SITE ON DESIGN CONTROL AUDITS
This article was originally published in The Gray Sheet
Executive Summary
A Health Industry Manufacturers Association proposal to allow manufacturers to select which of their devices will be inspected for design controls during the one-year transitional period for the requirements is "a reasonable approach," Robert Ruff, a consumer safety officer in FDA's New Jersey District Office, said at a May 30 agency/industry workshop on design controls in Baltimore.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.